| Date | Title | | | 08/30/10 | Marina Biotech Announces Allowance of Fundamental RNAi Delivery Patent From U.S. Patent Office| Patent Allowance Protects Marina Biotech Key Delivery Technology for RNAi Therapeutics
BOTHELL, WA, Aug 30, 2010 (MARKETWIRE via COMTEX) --Marina Biotech, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and development company, today announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for patent application U.S. 11/745,003 broadly covering amphoteric liposomal formulations, including the Company's proprietary SMARTICLES(R) technology, for delivery of s... |
|  | | 08/26/10 | Marina Biotech Sells Carbetocin Asset to Cypress Bioscience| BOTHELL, WA, Aug 26, 2010 (MARKETWIRE via COMTEX) --Marina Biotech, Inc. (NASDAQ: MRNA) announced today that it has entered into an Asset Purchase Agreement with Cypress Bioscience, Inc. (NASDAQ: CYPB) under which Cypress will acquire Marina Biotech's patent rights and technology related to Carbetocin. Marina Biotech will receive an upfront payment of $750,000 and potential milestone payments up to $27 million in exchange for the asset. Cypress will be responsible for all future development and ... |
| | | 08/24/10 | Marina Biotech Announces Issuance of a U.S. Patent Broadly Covering Its Amphoteric Liposomal siRNA Delivery Technology| Patent Further Strengthens Marina Biotech's RNA Delivery Intellectual Property Portfolio
BOTHELL, WA, Aug 24, 2010 (MARKETWIRE via COMTEX) --
Marina Biotech, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and development company, today announced that the U.S. Patent and Trademark Office has issued patent U.S. 7,780,983 covering processes for preparing amphoteric liposomes or SMARTICLES(R). Marina Biotech recently acquired the SMARTICLES(R) intellectual property portfolio of Novosom... |
| | | 08/12/10 | Marina Biotech, Inc. Announces Second Quarter 2010 Financial Results| Highlights Second Quarter and Recent Corporate Accomplishments
BOTHELL, WA, Aug 12, 2010 (MARKETWIRE via COMTEX) --
Marina Biotech, Inc. (NASDAQ: MRNAD), formerly MDRNA, Inc., a leading RNAi-based drug discovery and development company, today reported financial results for the second quarter ended June 30, 2010, and highlighted recent corporate accomplishments.
"In the second quarter and into the third quarter of 2010, we have realized over two years of diligent efforts to identify, acqu... |
| | | 08/05/10 | Marina Biotech, Inc. to Report Second Quarter Results on August 12, 2010 at 4:30 p.m. Eastern Time| BOTHELL, WA, Aug 05, 2010 (MARKETWIRE via COMTEX) --
Marina Biotech, Inc. (NASDAQ: MRNAD), formerly known as MDRNA, Inc., a leading RNAi-based drug discovery and development company, today announced that it will host a conference call with investors and security analysts on Thursday, August 12, 2010, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to provide a business update and discuss financial results for the second quarter ended June 30, 2010.
To participate in the live conference ... |
| | | 07/29/10 | Marina Biotech, Inc. Announces Upcoming Investor Conference Presentations| BOTHELL, WA, Jul 29, 2010 (MARKETWIRE via COMTEX) --
Marina Biotech, Inc. (NASDAQ: MRNAD), formerly known as MDRNA, Inc., a leading RNAi-based drug discovery and development company, today announced that J. Michael French, Marina's President and Chief Executive Officer, will provide an overview of the Company and its progress in key programs at the following upcoming conferences:
-- The BMO Capital Markets 10th Annual Focus on Healthcare Conference, on
Thursday, August 5 at 4:00 p.m. E... |
| | | 07/28/10 | Marina Biotech Acquires RNA Delivery Assets of Novosom AG| Patent Rights to SMARTICLES(R) Technology Strengthens Marina's Intellectual Property Position and Further Expands Its siRNA Delivery Technologies
BOTHELL, WA, Jul 28, 2010 (MARKETWIRE via COMTEX) -- Marina Biotech, Inc. (NASDAQ: MRNAD) announced today that the Company has acquired the intellectual property of Novosom AG of Halle, Germany for its SMARTICLES(R) liposomal-based delivery system in an all-stock transaction. The transaction further expands Marina's RNA delivery platform IP estate, w... |
| | | 07/27/10 | Marina Biotech and University of Helsinki Expand Collaboration to Discover Novel Targeting Peptides With Marina's Proprietary Trp Cage Library| Marina to Evaluate Candidate Peptides in Proprietary siRNA Delivery Systems
BOTHELL, WA, Jul 27, 2010 (MARKETWIRE via COMTEX) --
Marina Biotech, Inc. (NASDAQ: MRNAD) (formerly known as MDRNA, Inc.) and Dr. Pirjo Laakkonen at the University of Helsinki Biomedicum in Finland today announced the extension of their collaboration to identify novel peptides with preferential homing-like properties which allow the peptides to target specific tissues, including tumors. The collaboration will utilize... |
| | | 07/22/10 | MDRNA, Inc. Shareholders Approve Acquisition of Cequent Pharmaceuticals| Name Changed to Marina Biotech, Inc.; Reverse Stock Split Implemented
BOTHELL, WA, Jul 22, 2010 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and development company, announced that, at the Company's Annual Meeting of Shareholders held yesterday, MDRNA shareholders approved the issuance of shares of MDRNA common stock in connection with the proposed acquisition of Cequent Pharmaceuticals, Inc. (Proposal No. 1). MDRNA shareholders also approved an am... |
| | | 07/19/10 | MDRNA, Inc. Encourages Stockholders to Vote Their Shares| Proposal No.8 Requires the Affirmative Vote of a Majority of All Outstanding Shares; Company Will Effect a Reverse Split to Enable the Cequent Merger If Proposal No. 8 Does Not Achieve Requisite Votes
BOTHELL, WA, Jul 19, 2010 (MARKETWIRE via COMTEX) -- MDRNA, Inc.(NASDAQ: MRNA) announced today that it is encouraging all stockholders to promptly submit their voting instructions for the annual meeting of stockholders to be held on Wednesday, July 21, 2010, at 10:00 a.m. Eastern Time. Stockholde... |
| | | 06/09/10 | MDRNA, Inc. Expands Its Proprietary UNA Intellectual Property Portfolio by Acquiring Exclusive Rights to UNA-Based Diagnostics| Establishes Basis for a Nucleic Acid-Based Personalized Medicine Platform Through Exclusive Rights to Technologies for Both Therapeutics and Diagnostics
BOTHELL, WA, Jun 09, 2010 (MARKETWIRE via COMTEX) --MDRNA, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and development company, announced today that it obtained exclusive rights to develop, make, use and sell UNA (Unlocked Nucleobase Analog)-based diagnostics from RiboTask ApS, a privately held Denmark-based company specializing i... |
| | | 06/02/10 | MDRNA, Inc. to Present at 9th Annual Needham Healthcare Conference| BOTHELL, WA, Jun 02, 2010 (MARKETWIRE via COMTEX) --MDRNA, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and development company, today announced that it will be presenting at the 9th Annual Needham Healthcare Conference held at the New York Palace Hotel in New York City. J. Michael French, MDRNA's President and Chief Executive Officer, will provide a business update and overview of the Company on Wednesday, June 9, 2010 at 2:40 p.m. (Eastern Time).
To access the live webcast of the... |
| | | 05/13/10 | MDRNA, Inc. Announces First Quarter 2010 Financial Results| Highlights First Quarter and Recent Corporate Accomplishments
BOTHELL, WA, May 13, 2010 (MARKETWIRE via COMTEX) --MDRNA, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and development company, today reported financial results for the first quarter ended March 31, 2010, and recent corporate accomplishments.
"As we close in on the end of the second quarter 2010, we see the last twelve months as a year of building," stated J. Michael French, President and Chief Executive Officer of MD... |
| | | 05/12/10 | MDRNA, Inc. Selected as a "Best and Brightest" Technology Leader| Highlights Its Broad and Comprehensive RNAi Intellectual Property Estate at Bright Lights Conference 2010
BOTHELL, WA, May 12, 2010 (MARKETWIRE via COMTEX) --MDRNA, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and development company, today reported that MDRNA was chosen as a "Best and Brightest" technology leader by the MDB Capital Group based on the novelty, quality and industry impact of its innovative patent estate. The Company has a broad intellectual property estate of 17 iss... |
| | | 05/06/10 | MDRNA, Inc. Reports Novel Target Specificity Characteristics of Its Proprietary UsiRNA Technology for RNAi-based Therapeutics| UNA Technology Provides Essential Drug-Like Properties to RNAi-Based Therapeutics
BOTHELL, WA, May 06, 2010 (MARKETWIRE via COMTEX) --MDRNA, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and development company, today reported on advances made with the Company's proprietary UsiRNA construct for RNA interference (RNAi). The term UsiRNA denotes inclusion of unlocked nucleobase analogs (UNA) in the double-stranded oligonucleotide construct. UsiRNAs demonstrate enhanced specificity and ... |
| | | 05/05/10 | MDRNA, Inc. to Report First Quarter Results on May 13, 2010 at 4:30 p.m. Eastern Time| BOTHELL, WA, May 05, 2010 (MARKETWIRE via COMTEX) --MDRNA, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and development company, today announced that it will host a conference call with investors and security analysts on Thursday, May 13, 2010, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to provide a business update and discuss financial results for the first quarter ended March 31, 2010.
To participate in the live conference call, U.S. residents should dial 800-561-2693 and... |
| | | 05/04/10 | MDRNA, Inc. Announces Substantial Knockdown of a Liver Target via Systemic Delivery With Microgram Dosing Using Its Proprietary UsiRNA/DiLA2 Technology| Announces Early Collaborative Effort Bringing Total of On-Going Research Collaborations to Five
BOTHELL, WA, May 04, 2010 (MARKETWIRE via COMTEX) --MDRNA, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and development company, today reported substantial advances in the activity of UsiRNA constructs delivered by its DiLA2 delivery technology resulting in 50% knockdown of Factor VII (FVII) protein at a 80 microgram per kilogram dose via systemic delivery. The Company also announced an ... |
| | | 04/28/10 | MDRNA, Inc. Announces Combinations of UsiRNAs in Proprietary DiLA2 Delivery Technology Show Improved Efficacy in Bladder Cancer Model| 30%-50% Greater Efficacy Observed With UsiRNAs Targeting Multiple Genes Versus a Single Target Approach
BOTHELL, WA, Apr 28, 2010 (MARKETWIRE via COMTEX) --MDRNA, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and development company, today reported data demonstrating greater efficacy in tumor reduction in an orthotopic model of bladder cancer with multiple combinations of two UsiRNAs as compared to single target therapy. The data were presented by Michael V. Templin, Ph.D., Senior V... |
| | | 04/19/10 | MDRNA, Inc. Announces Patent Allowance Covering siRNA and Delivery Systems With Therapeutic Potential in Multiple Inflammatory Diseases| Allowance Covers siRNAs and Delivery Peptides Targeting a Key Regulator of Immune Cells: Tumor Necrosis Factor (TNF)
BOTHELL, WA, Apr 19, 2010 (MARKETWIRE via COMTEX) --MDRNA, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and development company, today announced that the Intellectual Property Office of New Zealand (IPONZ) has issued a Notice of Acceptance for patent application 553828, titled "Methods of Treating an Inflammatory Disease by Double-Stranded Ribonucleic Acid." Allowed ... |
| | | 04/12/10 | MDRNA, Inc. Announces Patent Allowance Covering Intranasal Formulations for Y2-Receptor Agonists| Allowance Broadens Portfolio for the Treatment of Obesity and Related Diseases
BOTHELL, WA, Apr 12, 2010 (MARKETWIRE via COMTEX) --MDRNA, Inc. (NASDAQ: MRNA), a leading RNA interference (RNAi)-based drug discovery and development company, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for patent application U.S. 12/234,547 covering formulations for the intranasal delivery of Y2 receptor selective agonists.
Y2-receptor agonists are a family ... |
| | | 04/05/10 | MDRNA, Inc. Announces Research Study With Pfizer| Activities to Focus on MDRNA's Proprietary RNAi Drug Discovery Platform -- UsiRNA Constructs and DiLA2 Delivery System
BOTHELL, WA, Apr 05, 2010 (MARKETWIRE via COMTEX) --MDRNA, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and development company, today announced a study effort with Pfizer (NYSE: PFE). The relationship will focus on the evaluation of MDRNA's proprietary di-alkylated amino acids (DiLA2) platform and UsiRNA constructs for RNA interference (RNAi). Additional details o... |
| | | 04/02/10 | MDRNA, Inc. Complies With NASDAQ Marketplace Rule 5250(b)(2)| BOTHELL, WA, Apr 02, 2010 (MARKETWIRE via COMTEX) --MDRNA, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and development company, today announced that the Company's independent registered public accounting firm, KPMG LLP, included an explanatory paragraph in their opinion on the Company's financial statements included in the recently filed Annual Report on Form 10-K for the year ended December 31, 2009, relating to the Company's ability to continue as a going concern.
"We continue t... |
| | | 04/01/10 | MDRNA, Inc. Acquires Cequent Pharmaceuticals| Expands Both Its Oncology Pipeline and RNAi Drug Discovery Platform Capabilities; Initiation of Phase 1 Trial in Familial Adenomatous Polyposis Expected in Second Quarter 2010; Transaction Funds Combined Operations Into December 2010
BOTHELL, WA and CAMBRIDGE, MA, Apr 01, 2010 (MARKETWIRE via COMTEX) --MDRNA, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and development company, and Cequent Pharmaceuticals, a pioneer in the development of novel products to deliver RNAi-based therape... |
| | | 03/29/10 | MDRNA, Inc. Announces Patent Allowance Covering Methods for Cell Specific Delivery of siRNAs| Patent Further Strengthens MDRNA's RNAi Delivery IP Estate
BOTHELL, WA, Mar 29, 2010 (MARKETWIRE via COMTEX) --MDRNA, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and development company, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for patent application U.S. 12/701,397 covering methods for the delivery of siRNAs as well as a broad array of compounds with pharmacological activity. The patent identifies and protects peptides tha... |
| | | 03/23/10 | MDRNA, Inc. Acquires Bridged Nucleic Acid (BNA) Patents to Broaden Its RNAi-Drug Discovery Platform| BNA Technology Provides Opportunity to Develop Single Stranded RNA Therapeutics for the Treatment of Human DiseasesBOTHELL, WA, Mar 23, 2010 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and development company, announced today that it has acquired intellectual property for bridged nucleic acids from Valeant Pharmaceuticals North America. Bridged nucleic acids (BNA) are novel nucleoside analogs in which the flexible ribose sugar is locked into a rigid... |
| | | 03/23/10 | MDRNA, Inc. Announces Fourth Quarter and Full Year 2009 Financial Results| Highlights Fourth Quarter and Recent Corporate Accomplishments; Regains Compliance With NASDAQ Marketplace Rule 5450(b)(2)(A)BOTHELL, WA, Mar 23, 2010 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and development company, today reported financial results for the fourth quarter and year ended December 31, 2009. Net loss for the fourth quarter of 2009 was approximately $0.8 million or $0.02 per share, compared to a net loss of approximately $12.3 millio... |
| | | 03/16/10 | MDRNA, Inc. to Report Fourth Quarter and Year-End 2009 Results on
March 23, 2010 at 4:30 p.m. Eastern Time| BOTHELL, WA, Mar 16, 2010 (MARKETWIRE via COMTEX) -- MDRNA, Inc. -- (NASDAQ: MRNA), a leading RNAi-based drug discovery
and development company, today announced that it will host a
conference call with investors and security analysts on Tuesday,
March 23, 2010, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to
provide a business update and discuss financial results for the
fourth quarter and fiscal year ended December 31, 2009.
To participate in the live conference call, U.S. residents... |
| | | 03/15/10 | MDRNA, Inc. Demonstrates the Potential for Greater Efficacy in Cancer
With an UsiRNA Combination Approach| Announces Early Collaborative Effort With AstraZeneca Innovation Center ChinaBOTHELL, WA, Mar 15, 2010 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and
development company, today announced enhanced efficacy for tumor
reduction when two UsiRNA were combined within a single formulation.
The UsiRNAs targeted two proteins survivin, a protein involved in
cell division and inhibition of apoptosis, and PLK1 (Polo-like Kinase
1), a protein involved in c... |
| | | 03/08/10 | MDRNA, Inc. Announces Upcoming Investor Conference Presentations| BOTHELL, WA, Mar 08, 2010 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and
development company, today announced that J. Michael French, MDRNA's
President and Chief Executive Officer, will provide an overview of
the Company and its progress in key programs at the following
upcoming conferences:
-- The ROTH 22nd Annual OC Growth Stock Conference, on Monday, March 15 at
4:30 p.m. Pacific Time at the Ritz-Carlton in Dana Point, California;
... |
| | | 02/08/10 | MDRNA, Inc. Reports Positive Results for Its Proprietary siRNA
Delivery Technology| Data Demonstrates the Potential for Long-Term Stability of Drug ProductsBOTHELL, WA, Feb 08, 2010 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and
development company, today announced that its lead delivery system
formulation demonstrated exceptional stability over a one year period
under a variety of conditions. The DiLA2 formulation maintained in
vivo knockdown activity with no observed loss in potency over the
course of the year-long study w... |
| | | 02/08/10 | MDRNA, Inc. Receives Compliance Extension From NASDAQ| BOTHELL, WA, Feb 08, 2010 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) announced that it received a letter on
February 5, 2010 from The NASDAQ Stock Market, Inc. notifying the
Company that, as a result of Securities and Exchanges Commission
(SEC) approved changes to NASDAQ Listing Rules, MDRNA now has a grace
period of 180 days from its initial notice of non-compliance in which
to regain compliance with the $50 million minimum Market Value of
Listed Securities (MVLS) for continued... |
| | | 02/01/10 | MDRNA, Inc. to Present at the 12th Annual BIO CEO & Investor
Conference| Will Also Participate in a Panel Discussion on RNAi-Based TechnologyBOTHELL, WA, Feb 01, 2010 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and
development company, today announced that it will present at the 12th
Annual BIO CEO & Investor Conference being held at the Waldorf
Astoria Hotel in New York City, New York. J. Michael French, MDRNA's
President and Chief Executive Officer, will provide an overview of
the Company and its progress in k... |
| | | 01/26/10 | MDRNA, Inc. Issued Patent for the Use of Nucleic Acids to Treat Cancer| MDRNA IP Estate Extends Into AsiaBOTHELL, WA, Jan 26, 2010 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and development company, today announced that the State Intellectual Property Office of the People's Republic of China (PRC) has issued a Notification of Granting Patent Rights for PRC 200480018784 which includes the use of nucleic acids, e.g., an siRNA, for the treatment of cancer. The patent describes modulation of claudins, which are proteins im... |
| | | 01/21/10 | MDRNA, Inc. Announces Allowance of European Patent Covering Formulations for Rapid Acting Insulin| Allowance Further Strengthens Intranasal IP Portfolio and Potential for Out-Licensing AssetsBOTHELL, WA, Jan 21, 2010 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and development company, today announced that the European Patent Office intends to grant a patent for application EP06826368 covering formulations for the intranasal delivery of rapid acting insulin, and its use for the treatment of diabetes.
"While our focus remains the development of R... |
| | | 01/19/10 | MDRNA Demonstrates Significantly Reduced Off-Target Activity for Proprietary RNAi-Based Compounds| Results Show Greater Target Specificity for Novel UsiRNA Constructs Based on Proprietary Unlocked Nucleobase Analog TechnologyBOTHELL, WA, Jan 19, 2010 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and
development company, today announced the presentation of data
highlighting the ability of the UsiRNA construct to significantly
minimize off-target effects while maintaining potent RNA Interference
(RNAi) activity. Narendra Vaish, Ph.D., MBA, Assoc... |
| | | 01/14/10 | MDRNA, Inc. Raises $5.5 Million in Registered Direct Offering| BOTHELL, WA, Jan 14, 2010 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) announced today that it has entered into a definitive agreement with investors to raise gross proceeds of $5.5 million through a registered direct offering. Under the terms of the agreement, the Company will sell 5,385,557 shares of its common stock at $1.02125 per share. As part of the transaction, the investors also will receive warrants, with a 5-year term, to purchase 3,500,612 shares of common stock at an exerci... |
| | | 01/13/10 | MDRNA Reports Potent Anti-Tumor Activity Against Multiple Targets in Liver and Bladder Cancer| Announces Additional Early Collaborative Effort With Major International Pharmaceutical CompanyBOTHELL, WA, Jan 13, 2010 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and development company, reported today in vivo data for bladder and liver cancer demonstrating further advancement of the Company's oncology programs. The Company reported a reduction in tumor growth in both liver and bladder cancers by targeting genes key to tumor progression, via both... |
| |
|
